{"url":"https://newsforagent.com/news/2026-10-30/astrazeneca-enhertu-prix-galien-award","markdown_url":"https://newsforagent.com/news/2026-10-30/astrazeneca-enhertu-prix-galien-award.md","title":"AstraZeneca's Enhertu Wins 2026 Prix Galien Award","headline":"AstraZeneca and Daiichi Sankyo's Enhertu Takes 2026 International Prix Galien","description":"Enhertu, AstraZeneca and Daiichi Sankyo's HER2-directed antibody drug conjugate, won the 2026 International Prix Galien Award for Best Biotechnology Product.","section":"Business","published_at":"2026-10-30T11:26:07+00:00","modified_at":"2026-10-30T11:26:07+00:00","author":"News Desk","key_takeaways":["Enhertu won the 2026 International Prix Galien Award for Best Biotechnology Product, its second Prix Galien honor after the 2024 USA award.","The award was presented at the American Museum of Natural History in New York on October 29, 2026.","Daiichi Sankyo President and CEO Hiroyuki Okuzawa said Enhertu has transformed the treatment and classification of metastatic breast cancer."],"companies":[{"name":"AstraZeneca","is_primary":true,"profile_url":"https://akta.pro/company-profiles/000026p/astrazeneca","website":"https://www.astrazeneca.com"},{"name":"Daiichi Sankyo","is_primary":false,"profile_url":"https://akta.pro/company-profiles/0003std/daiichi-sankyo","website":"http://www.daiichisankyo.com"}],"source":{"publisher":"Business Wire","title":"AstraZeneca's Enhertu wins 2026 Prix Galien award","url":"https://www.businesswire.com/news/home/20261029264668/en/"},"other_sources":[],"tags":["Business","AstraZeneca","Daiichi Sankyo"],"body_markdown":"Enhertu, the HER2-directed antibody drug conjugate developed by Daiichi Sankyo and AstraZeneca, won the 2026 International Prix Galien Award for Best Biotechnology Product, the companies said in a [Business Wire](https://www.businesswire.com/news/home/20261029264668/en/) announcement. The award, given every two years by The Galien Foundation, was presented at a ceremony in New York on October 29, 2026.\n\n## Enhertu's Second Prix Galien Honor\n\nEnhertu (trastuzumab deruxtecan) received the International Prix Galien Award after taking the Prix Galien USA Award for Best Biotechnology Product in 2024. The Galien Foundation describes the Prix Galien as the industry's equivalent of the Nobel Prize, and medicines recognized with a National Prix Galien Award within the prior two years are eligible for the international honor. Enhertu was one of six nominees for the 2026 award, which is selected by an international committee of chairs from member nations including Japan, the UK, the USA, France, Germany and China.\n\nEnhertu is a specifically engineered HER2-directed DXd antibody drug conjugate discovered by [Daiichi Sankyo](https://akta.pro/company-profiles/0003std/daiichi-sankyo) and jointly developed and commercialized with [AstraZeneca](https://akta.pro/company-profiles/000026p/astrazeneca). Daiichi Sankyo reported H1 revenue up 19.7% and core operating profit up 46.9%, driven by Enhertu and Datroway, according to TradingView.\n\n\"We are honored to receive this second Prix Galien award, which recognizes the impressive advances Enhertu has made possible for certain patients with cancer around the world,\" said Hiroyuki Okuzawa, President and CEO of Daiichi Sankyo. Okuzawa said that since its first U.S. approval in 2019, Enhertu has transformed the treatment and classification of metastatic breast cancer by establishing HER2 low and HER2 ultralow breast cancer as clinically distinct patient segments.\n\n## AstraZeneca's Oncology Scale Behind Enhertu\n\nAstraZeneca is a global pharmaceutical company that develops and markets oncology, cardiometabolic, rare disease and respiratory prescription medicines, including the ADC therapies Enhertu and Datroway, according to akta.pro [company records](https://akta.pro/company-data). The same records show full-year revenue of $60.4 billion with a 17.2% net margin, and Q1 2026 revenue of $12.68 billion, up 19% with 26% oncology sales growth. Management has guided toward an annual sales target of $80 billion by 2030, with 20 planned drug launches.\n\n## AstraZeneca's Recent Quarter and Pipeline Push\n\nAstraZeneca reported third-quarter pretax profit of $3.96 billion, up from a year earlier, MarketScreener reported. The company also announced a restructuring programme targeting about $1.5 billion in savings to support pipeline investments, with up to $2 billion in one-time charges and completion expected largely by the end of 2029, according to MarketScreener. In July, AstraZeneca's drug Wainua failed a major late-stage heart disease trial, Endpoints News reported.\n\n## What Comes Next for Enhertu\n\nEnhertu is approved in more than 100 countries or regions for unresectable or metastatic HER2 positive breast cancer after a prior anti-HER2-based regimen, and in more than 75 countries or regions for HR positive, HER2 low or HER2 ultralow breast cancer after endocrine therapy, based on the DESTINY-Breast03 and DESTINY-Breast06 trials.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}